Year archive

Sandoz Group AG — 2024 filings

All 19 regulatory filings released by Sandoz Group AG (SDZ) in 2024, sourced directly from the official regulator.

19 Filings

2024 Period

2024 filings (19)

Filing	Released	Lang
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation Legal Proceedings Report	2024-12-17	English
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio Regulatory Filings	2024-11-15	English
Sandoz reports third-quarter and nine-month 2024 sales Earnings Release Q3 2024	2024-10-30	English
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position Regulatory Filings	2024-08-12	English
Sandoz reports second-quarter sales and half-year 2024 results Earnings Release H1 2024	2024-08-08	English
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Regulatory Filings	2024-07-25	English
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US M&A Activity	2024-07-01	English
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe Regulatory Filings	2024-05-22	English
Sandoz reports first quarter 2024 sales Earnings Release Q1 2024	2024-05-07	English
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG AGM Information	2024-04-30	English
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering Regulatory Filings	2024-04-22	English
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines Earnings Release FY 2023	2024-03-21	English
Sandoz reports fourth quarter 2023 sales and full-year 2023 results Earnings Release FY 2023	2024-03-13	English
Sandoz receives FDA approval for first and only denosumab biosimilars Regulatory Filings	2024-03-05	English
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market Regulatory Filings	2024-03-04	English
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs Legal Proceedings Report	2024-02-29	English
Sandoz announces changes in the Board of Directors Board/Management Information	2024-02-01	English
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany Regulatory Filings	2024-01-31	English
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market M&A Activity	2024-01-22	English